{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:16:49Z","timestamp":1783660609993,"version":"3.55.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Folia Microbiol"],"DOI":"10.1007\/s12223-026-01548-5","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:23:39Z","timestamp":1783653819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From symptom management to immune prevention: a comprehensive review of chikungunya treatment and vaccine development"],"prefix":"10.1007","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinglei","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxian","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukuan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueshui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Hin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4265-5833","authenticated-orcid":false,"given":"Zhangang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"1548_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.antiviral.2017.09.016","volume":"149","author":"R Abdelnabi","year":"2018","unstructured":"Abdelnabi R, Jochmans D, Verbeken E et al (2018) Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection. Antiviral Res 149:113\u2013117","journal-title":"Antiviral Res"},{"key":"1548_CR2","doi-asserted-by":"crossref","unstructured":"Alagarasu K, Kharikar D, Roy D et al (2025) Anti-chikungunya Activity of a Cinnamic Acid Derivative: An In Vitro and In Silico Study. Mol Biotechnol","DOI":"10.1007\/s12033-025-01461-1"},{"key":"1548_CR3","doi-asserted-by":"crossref","unstructured":"Albulescu IC, White-Scholten L, Tas A et al (2020) Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection. Viruses 12(3)","DOI":"10.3390\/v12030314"},{"key":"1548_CR4","doi-asserted-by":"crossref","unstructured":"Amaral JK, Taylor PC, Teixeira MM et al (2019) The Clinical Features, Pathogenesis and Methotrexate Therapy of Chronic Chikungunya Arthritis. Viruses 11(3)","DOI":"10.3390\/v11030289"},{"issue":"4","key":"1548_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007316","volume":"13","author":"MT Ar\u00e9valo","year":"2019","unstructured":"Ar\u00e9valo MT, Huang Y, Jones CA, Ross TM (2019) Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice. PLoS Negl Trop Dis 13(4):e0007316","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"1548_CR6","doi-asserted-by":"publisher","first-page":"e0008355","DOI":"10.1371\/journal.pntd.0008355","volume":"06","author":"M Arif","year":"2020","unstructured":"Arif M, Tauran P, Kosasih H et al (2020) Chikungunya in Indonesia: Epidemiology and diagnostic challenges. PLoS Negl Trop Dis 06(6):e0008355","journal-title":"PLoS Negl Trop Dis"},{"key":"1548_CR7","doi-asserted-by":"crossref","unstructured":"Barry M, Temsah MH, Al-Tawfiq JA, Memish ZA (2026) Travel-Related Challenges of Chikungunya Virus and Vaccination Options. J Epidemiol Glob Health 16(1)","DOI":"10.1007\/s44197-026-00518-x"},{"key":"1548_CR8","doi-asserted-by":"crossref","unstructured":"Battisti V, Urban E, Langer T (2021) Antivirals against the Chikungunya Virus. Viruses 13(7)","DOI":"10.3390\/v13071307"},{"issue":"9816","key":"1548_CR9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(11)60281-X","volume":"379","author":"FJ Burt","year":"2012","unstructured":"Burt FJ, Rolph MS, Rulli NE et al (2012) Chikungunya: a re-emerging virus. Lancet 379(9816):662\u2013671","journal-title":"Lancet"},{"issue":"3","key":"1548_CR10","first-page":"211","volume":"36","author":"C Caglioti","year":"2013","unstructured":"Caglioti C, Lalle E, Castilletti C et al (2013) Chikungunya virus infection: an overview. New Microbiol 36(3):211\u2013227","journal-title":"New Microbiol"},{"key":"1548_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1095549","volume":"10","author":"L Cai","year":"2022","unstructured":"Cai L, Hu X, Liu S et al (2022) The research progress of chikungunya fever. Front Public Health 10:1095549","journal-title":"Front Public Health"},{"key":"1548_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.591885","volume":"11","author":"RK Campos","year":"2020","unstructured":"Campos RK, Preciado-Llanes L, Azar SR et al (2020) Adenoviral-vectored mayaro and chikungunya virus vaccine candidates afford partial cross-protection from lethal challenge in A129 mouse model. Front Immunol 11:591885","journal-title":"Front Immunol"},{"key":"1548_CR13","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0431-2019","volume":"53","author":"J Cerbino-Neto","year":"2020","unstructured":"Cerbino-Neto J, Mesquita EC, Amancio RT, Brasil P (2020) Events preceding death among chikungunya virus infected patients: a systematic review. Rev Soc Bras Med Trop 53:e04312019","journal-title":"Rev Soc Bras Med Trop"},{"issue":"3","key":"1548_CR14","first-page":"175","volume":"19","author":"YS Chan","year":"2016","unstructured":"Chan YS, Khoo KS, Sit NWW (2016) Investigation of twenty selected medicinal plants from Malaysia for anti-Chikungunya virus activity. Int Microbiol 19(3):175\u2013182","journal-title":"Int Microbiol"},{"issue":"12","key":"1548_CR15","doi-asserted-by":"publisher","first-page":"e0008910","DOI":"10.1371\/journal.pntd.0008910","volume":"14","author":"H Chen","year":"2020","unstructured":"Chen H, Min N, Ma L et al (2020) Adenovirus vectored IFN-\u03b1 protects mice from lethal challenge of Chikungunya virus infection. PLoS Negl Trop Dis 14(12):e0008910","journal-title":"PLoS Negl Trop Dis"},{"key":"1548_CR16","doi-asserted-by":"crossref","unstructured":"Chen LH, Fritzer A, Hochreiter R et al (2024) From bench to clinic: the development of VLA1553\/IXCHIQ, a live-attenuated chikungunya vaccine. J Travel Med 31(7)","DOI":"10.1093\/jtm\/taae123"},{"key":"1548_CR17","doi-asserted-by":"crossref","unstructured":"Chen LH, Fritzer A, Hochreiter R et al (2024) From bench to clinic: the development of VLA1553\/IXCHIQ, a live-attenuated chikungunya vaccine. J Travel Med","DOI":"10.1093\/jtm\/taae123"},{"key":"#cr-split#-1548_CR18.1","unstructured":"Chikungunya Vaccine Information for Healthcare Providers: Centers for Disease Control and Prevention (2026) [updated January 23, 2026"},{"key":"#cr-split#-1548_CR18.2","unstructured":"cited 2026 May 19]. Available from: https:\/\/www.cdc.gov\/chikungunya\/hcp\/vaccines\/index.html"},{"key":"1548_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","volume":"12","author":"A Ciabattini","year":"2018","unstructured":"Ciabattini A, Nardini C, Santoro F et al (2018) Vaccination in the elderly: The challenge of immune changes with aging. Semin Immunol 12:40:83\u201394","journal-title":"Semin Immunol"},{"issue":"3","key":"1548_CR20","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11030-023-10654-2","volume":"28","author":"RN Dash","year":"2024","unstructured":"Dash RN, Prabhudutta M, De S et al (2024) Conjugates of ibuprofen inhibit CHIKV infection and inflammation. Mol Divers 28(3):1261\u20131272","journal-title":"Mol Divers"},{"issue":"9","key":"1548_CR21","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1074\/jbc.M113.503433","volume":"289","author":"PK Das","year":"2014","unstructured":"Das PK, Merits A, Lulla A (2014) Functional Cross-talk between Distant Domains of Chikungunya Virus Non-structural Protein 2 Is Decisive for Its RNA-modulating Activity. J Biol Chem 289(9):5635\u20135653","journal-title":"J Biol Chem"},{"issue":"6","key":"1548_CR22","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.4269\/ajtmh.19-0122","volume":"06","author":"IM Deeba","year":"2019","unstructured":"Deeba IM, Hasan MM, Al Mosabbir A et al (2019) Manifestations of Atypical Symptoms of Chikungunya during the Dhaka Outbreak (2017) in Bangladesh. Am J Trop Med Hyg 06(6):1545\u20131548","journal-title":"Am J Trop Med Hyg"},{"key":"1548_CR23","first-page":"81","volume":"435","author":"VR DeFilippis","year":"2022","unstructured":"DeFilippis VR (2022) Chikungunya Virus Vaccines: Platforms, Progress, and Challenges. Curr Top Microbiol Immunol 435:81\u2013106","journal-title":"Curr Top Microbiol Immunol"},{"key":"#cr-split#-1548_CR24.1","unstructured":"FDA Update on the Safety of Ixchiq (Chikungunya Vaccine Live). FDA Suspends Biologics License: FDA Safety Communication: U.S. Food and Drug Administration (2025) [updated August 22, 2025"},{"key":"#cr-split#-1548_CR24.2","unstructured":"cited 2026 May 18]. Available from: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/fda-update-safety-ixchiq-chikungunya-vaccine-live-fda-suspends-biologics-license-fda-safety"},{"key":"1548_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/2040206618807580","volume":"26","author":"EJ Franco","year":"2018","unstructured":"Franco EJ, Rodriquez JL, Pomeroy JJ et al (2018) The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines. Antivir Chem Chemother 26:2040206618807580","journal-title":"Antivir Chem Chemother"},{"key":"1548_CR26","doi-asserted-by":"crossref","unstructured":"Franco EJ, Tao X, Hanrahan KC et al (2021) Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines. Microorganisms 9(2)","DOI":"10.3390\/microorganisms9020307"},{"issue":"2","key":"1548_CR27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta Y, Gowen BB, Takahashi K et al (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100(2):446\u2013454","journal-title":"Antiviral Res"},{"key":"1548_CR28","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arriaza J, Esteban M, L\u00f3pez D (2021) Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus. Biomedicines 9(9)","DOI":"10.3390\/biomedicines9091122"},{"key":"1548_CR29","doi-asserted-by":"crossref","unstructured":"Graham VA, Easterbrook L, Rayner E et al (2024) Comparison of Chikungunya Virus-Induced Disease Progression and Pathogenesis in Type-I Interferon Receptor-Deficient Mice (A129) and Two Wild-Type (129Sv\/Ev and C57BL\/6) Mouse Strains. Viruses 16(10)","DOI":"10.3390\/v16101534"},{"issue":"4","key":"1548_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14760584.2019.1562908","volume":"18","author":"C Gerke","year":"2019","unstructured":"Gerke C, Frantz PN, Ramsauer K, Tangy F (2019) Measles-vectored vaccine approaches against viral infections: a focus on Chikungunya. Expert Rev Vaccines 18(4):393\u2013403","journal-title":"Expert Rev Vaccines"},{"key":"1548_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.virol.2023.06.001","volume":"08","author":"M Gosavi","year":"2023","unstructured":"Gosavi M, Kulkarni-Munje A, Patil HP (2023) Dual pattern recognition receptor ligands CL401, CL413, and CL429 as adjuvants for inactivated chikungunya virus. Virology 08:585:82\u201390","journal-title":"Virology"},{"key":"1548_CR32","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x2023e12557","volume":"56","author":"WJP Gotay","year":"2023","unstructured":"Gotay WJP, Rodrigues RO, Yaochite JNU (2023) Influence of host genetic polymorphisms involved in immune response and their role in the development of Chikungunya disease: a review. Braz J Med Biol Res 56:e12557","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"1548_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-00663-6","volume":"15","author":"N Gumpangseth","year":"2025","unstructured":"Gumpangseth N, Villarroel PMS, Diack A et al (2025) IFITMs exhibit antiviral activity against Chikungunya and Zika virus infection via the alteration of TLRs and RLRs signaling pathways. Sci Rep 15(1):15769","journal-title":"Sci Rep"},{"key":"1548_CR34","doi-asserted-by":"publisher","first-page":"2651466","DOI":"10.1080\/22221751.2026.2651466","volume":"25","author":"Y Guo","year":"2026","unstructured":"Guo Y, Xiang Y, Zheng M et al (2026) Maternal Chikungunya Virus Infection and Pregnancy Outcomes: A Global Systematic Review and Meta-Analysis of Vertical Transmission Dynamics and Associated Morbidity. Emerg Microbes Infect 25:2651466","journal-title":"Emerg Microbes Infect"},{"issue":"5","key":"1548_CR35","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1128\/JVI.03453-13","volume":"88","author":"D Halleng\u00e4rd","year":"2014","unstructured":"Halleng\u00e4rd D, Kakoulidou M, Lulla A et al (2014) Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL\/6 mice. J Virol 88(5):2858\u20132866","journal-title":"J Virol"},{"issue":"22","key":"1548_CR36","doi-asserted-by":"publisher","first-page":"13333","DOI":"10.1128\/JVI.01926-14","volume":"88","author":"D Halleng\u00e4rd","year":"2014","unstructured":"Halleng\u00e4rd D, Lum FM, K\u00fcmmerer BM et al (2014) Prime-boost immunization strategies against Chikungunya virus. J Virol 88(22):13333\u201343","journal-title":"J Virol"},{"key":"1548_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herv\u00e9","year":"2019","unstructured":"Herv\u00e9 C, Laup\u00e8ze B, Del Giudice G et al (2019) The how\u2019s and what\u2019s of vaccine reactogenicity. NPJ Vaccines 4:39","journal-title":"NPJ Vaccines"},{"issue":"2","key":"1548_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.20506\/rst.34.2.2373","volume":"34","author":"PF Horwood","year":"2015","unstructured":"Horwood PF, Buchy P (2015) Chikungunya. Rev Sci Tech 34(2):479\u201389","journal-title":"Rev Sci Tech"},{"key":"1548_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2022.106408","volume":"231","author":"AA Irekeola","year":"2022","unstructured":"Irekeola AA, Engku Nur Syafirah EAR, Islam MA, Shueb RH (2022) Global prevalence of dengue and chikungunya coinfection: a systematic review and meta-analysis of 43,341 participants. Acta Trop 231:106408","journal-title":"Acta Trop"},{"issue":"6","key":"1548_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2183","volume":"7","author":"H Irfan","year":"2024","unstructured":"Irfan H, Ahmed A (2024) Advancements in chikungunya virus management: FDA approval of ixchiq vaccine and global perspectives. Health Sci Rep 7(6):e2183","journal-title":"Health Sci Rep"},{"issue":"2","key":"1548_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/00325481.2019.1561916","volume":"131","author":"D Kellstein","year":"2019","unstructured":"Kellstein D, Fernandes L (2019) Symptomatic treatment of dengue: should the NSAID contraindication be reconsidered? Postgrad Med 131(2):109\u2013116","journal-title":"Postgrad Med"},{"key":"1548_CR42","doi-asserted-by":"crossref","unstructured":"Kempster SL, Ferguson D, Ham C et al (2025) Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model. Viruses 17(4)","DOI":"10.3390\/v17040550"},{"issue":"1","key":"1548_CR43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12929-021-00778-8","volume":"28","author":"S Khongwichit","year":"2021","unstructured":"Khongwichit S, Chansaenroj J, Chirathaworn C, Poovorawan Y (2021) Chikungunya virus infection: molecular biology, clinical characteristics, and epidemiology in Asian countries. J Biomed Sci 28(1):84","journal-title":"J Biomed Sci"},{"issue":"43","key":"1548_CR44","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1016\/j.vaccine.2012.07.072","volume":"30","author":"M Kumar","year":"2012","unstructured":"Kumar M, Sudeep AB, Arankalle VA (2012) Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 30(43):6142\u20136149","journal-title":"Vaccine"},{"key":"1548_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.antiviral.2016.07.025","volume":"134","author":"SC Kuo","year":"2016","unstructured":"Kuo SC, Wang YM, Ho YJ et al (2016) Suramin treatment reduces chikungunya pathogenesis in mice. Antiviral Res 134:89\u201396","journal-title":"Antiviral Res"},{"issue":"1","key":"1548_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-025-02182-2","volume":"10","author":"X Liang","year":"2025","unstructured":"Liang X, Zhou Y, Yang Y et al (2025) CHIKV mRNA vaccines encoding conserved structural\/envelope proteins confer broad cross-lineage protection against infection. Signal Transduct Target Ther 10(1):98","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1548_CR47","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01143-21","volume":"96","author":"MC Locke","year":"2022","unstructured":"Locke MC, Fox LE, Dunlap BF et al (2022) Interferon alpha, but not interferon beta, acts early to control chronic Chikungunya virus pathogenesis. J Virol 96(1):e0114321","journal-title":"J Virol"},{"key":"1548_CR48","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Camacho C, Kim YC, Blight J et al (2019) Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus. Viruses 11(4)","DOI":"10.3390\/v11040322"},{"issue":"1","key":"1548_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32431-9","volume":"13","author":"V Mangala Prasad","year":"2022","unstructured":"Mangala Prasad V, Blijleven JS, Smit JM, Lee KK (2022) Visualization of conformational changes and membrane remodeling leading to genome delivery by viral class-II fusion machinery. Nat Commun 13(1):4772","journal-title":"Nat Commun"},{"issue":"35","key":"1548_CR50","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.2174\/1381612826666200707132920","volume":"26","author":"GP Martinez","year":"2020","unstructured":"Martinez GP, Zabaleta ME, Di Giulio C et al (2020) The role of chloroquine and hydroxychloroquine in immune regulation and diseases. Curr Pharm Des 26(35):4467\u20134485","journal-title":"Curr Pharm Des"},{"issue":"10","key":"1548_CR51","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3855\/jidc.6670","volume":"9","author":"S Mattar","year":"2015","unstructured":"Mattar S, Miranda J, Pinzon H et al (2015) Outbreak of Chikungunya virus in the north Caribbean area of Colombia: clinical presentation and phylogenetic analysis. J Infect Dev Ctries 9(10):1126\u201332","journal-title":"J Infect Dev Ctries"},{"key":"1548_CR52","doi-asserted-by":"crossref","unstructured":"Maurer G, Buerger V, Larcher-Senn J et al (2025) Comprehensive Assessment of Reactogenicity and Safety of the Live-Attenuated Chikungunya Vaccine (IXCHIQ\u00ae). Vaccines (Basel) 13(6)","DOI":"10.3390\/vaccines13060576"},{"key":"1548_CR53","doi-asserted-by":"crossref","unstructured":"Mercier A, Obadia T, Carraretto D et al (2022) Impact of temperature on dengue and chikungunya transmission by the mosquito Aedes albopictus. Sci Rep 12(1)","DOI":"10.1038\/s41598-022-10977-4"},{"key":"1548_CR54","doi-asserted-by":"crossref","unstructured":"Micheleto JPC, Melo KA, Veloso FCS et al (2025) Risk factors for mortality in patients with chikungunya: A systematic review and meta-analysis. Trop Med Int Health","DOI":"10.1111\/tmi.14088"},{"key":"1548_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/srep20122","volume":"6","author":"P Mishra","year":"2016","unstructured":"Mishra P, Kumar A, Mamidi P et al (2016) Inhibition of chikungunya virus replication by 1-[(2-methylbenzimidazol-1-yl) methyl]-2-oxo-indolin-3-ylidene] amino] thiourea(MBZM-N-IBT). Sci Rep 6:20122","journal-title":"Sci Rep"},{"issue":"3","key":"1548_CR56","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/infdis\/jiw111","volume":"214","author":"K Muthumani","year":"2016","unstructured":"Muthumani K, Block P, Flingai S et al (2016) Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus. J Infect Dis 214(3):369\u2013378","journal-title":"J Infect Dis"},{"issue":"5","key":"1548_CR57","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1097\/MS9.0000000000004917","volume":"88","author":"M Mudasir","year":"2026","unstructured":"Mudasir M, Kanwal W, Narjis K et al (2026) Vimkunya vaccine: a breakthrough in combating chikungunya. Ann Med Surg (Lond) 88(5):2725\u20132727","journal-title":"Ann Med Surg (Lond)"},{"issue":"4","key":"1548_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2441","volume":"33","author":"JAL Nunes","year":"2023","unstructured":"Nunes JAL, Sousa JR, Smith VC et al (2023) Immunological impact of cytokines on the chikungunya virus pathophysiology: a literature narrative review. Rev Med Virol 33(4):e2441","journal-title":"Rev Med Virol"},{"issue":"4","key":"1548_CR59","doi-asserted-by":"publisher","first-page":"620","DOI":"10.23736\/S1973-9087.21.06520-5","volume":"57","author":"IL Neumann","year":"2021","unstructured":"Neumann IL, de Oliveira DA, de Barros EL et al (2021) Resistance exercises improve physical function in chronic Chikungunya fever patients: a randomized controlled trial. Eur J Phys Rehabil Med 57(4):620\u2013629","journal-title":"Eur J Phys Rehabil Med"},{"issue":"1","key":"1548_CR60","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2529889","volume":"14","author":"CN Orji","year":"2025","unstructured":"Orji CN, Loeanurit N, Pham VC et al (2025) Chlorinated biscoumarins inhibit chikungunya virus replication in cell-based and animal models. Emerg Microbes Infect 14(1):2529889","journal-title":"Emerg Microbes Infect"},{"key":"1548_CR61","doi-asserted-by":"crossref","unstructured":"Peng C, Zhang D, Li C et al (2022) Rhinolophus sinicus virome revealed multiple novel mosquito-borne zoonotic viruses. Front Cell Infect Microbiol 12","DOI":"10.3389\/fcimb.2022.960507"},{"key":"1548_CR62","doi-asserted-by":"crossref","unstructured":"Phadungsombat J, Imad H, Rahman M et al (2020) A Novel Sub-Lineage of Chikungunya Virus East\/Central\/South African Genotype Indian Ocean Lineage Caused Sequential Outbreaks in Bangladesh and Thailand. Viruses 12(11)","DOI":"10.3390\/v12111319"},{"issue":"24389","key":"1548_CR63","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1016\/j.vaccine.2019.10.046","volume":"02","author":"SA Plotkin","year":"2020","unstructured":"Plotkin SA (2020) Updates on immunologic correlates of vaccine-induced protection. Vaccine 02(24389):2250\u20132257","journal-title":"Vaccine"},{"key":"1548_CR64","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fimmu.2020.00287","volume":"11","author":"CM Poh","year":"2020","unstructured":"Poh CM, Chan YH, Ng LFP (2020) Role of T Cells in Chikungunya Virus Infection and Utilizing Their Potential in Anti-Viral Immunity. Front Immunol 11:287","journal-title":"Front Immunol"},{"key":"1548_CR65","doi-asserted-by":"crossref","unstructured":"Powers AM (2018) Vaccine and Therapeutic Options To Control Chikungunya Virus. Clin Microbiol Rev 31(1)","DOI":"10.1128\/CMR.00104-16"},{"key":"1548_CR66","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.virol.2019.04.007","volume":"533","author":"S Raghavendhar","year":"2019","unstructured":"Raghavendhar S, Tripati PK, Ray P, Patel AK (2019) Evaluation of medicinal herbs for Anti-CHIKV activity. Virology 533:45\u201349","journal-title":"Virology"},{"issue":"6","key":"1548_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012254","volume":"18","author":"K Rama","year":"2024","unstructured":"Rama K, de Roo AM, Louwsma T et al (2024) Clinical outcomes of chikungunya: a systematic literature review and meta-analysis. PLoS Negl Trop Dis 18(6):e0012254","journal-title":"PLoS Negl Trop Dis"},{"issue":"suppl 5","key":"1548_CR68","doi-asserted-by":"publisher","first-page":"S500","DOI":"10.1093\/infdis\/jiw369","volume":"214","author":"K Ramsauer","year":"2016","unstructured":"Ramsauer K, Tangy F (2016) Chikungunya Virus Vaccines: Viral Vector-Based Approaches. J Infect Dis 214(suppl 5):S500\u2013s505","journal-title":"J Infect Dis"},{"issue":"6","key":"1548_CR69","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s10067-016-3429-0","volume":"36","author":"V Ravindran","year":"2017","unstructured":"Ravindran V, Alias G (2017) Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study. Clin Rheumatol 36(6):1335\u20131340","journal-title":"Clin Rheumatol"},{"issue":"2239210165","key":"1548_CR70","first-page":"2718","volume":"12","author":"EC Reisinger","year":"2019","unstructured":"Reisinger EC, Tschismarov R, Beubler E et al (2019) Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet 12(2239210165):2718\u20132727","journal-title":"Lancet"},{"issue":"10487","key":"1548_CR71","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/S0140-6736(25)00345-9","volume":"405","author":"JS Richardson","year":"2025","unstructured":"Richardson JS, Anderson DM, Mendy J et al (2025) Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 405(10487):1343\u20131352","journal-title":"Lancet"},{"key":"1548_CR72","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jbmt.2020.10.022","volume":"25","author":"AV Rolim de Oliveira","year":"2021","unstructured":"Rolim de Oliveira AV, Maria de Lima-Ten\u00f3rio P, Ever de Almeida MC et al (2021) Physiotherapeutic evaluation and intervention proposal on a patient with post-chikungunya chronic arthritis. J Bodyw Mov Ther 25:199\u2013204","journal-title":"J Bodyw Mov Ther"},{"issue":"7","key":"1548_CR73","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s10067-015-2979-x","volume":"34","author":"V Rosario","year":"2015","unstructured":"Rosario V, Munoz-Louis R, Valdez T et al (2015) Chikungunya infection in the general population and in patients with rheumatoid arthritis on biological therapy. Clin Rheumatol 34(7):1285\u20137","journal-title":"Clin Rheumatol"},{"issue":"5","key":"1548_CR74","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/infdis\/jiz202","volume":"220","author":"SL Rossi","year":"2019","unstructured":"Rossi SL, Comer JE, Wang E et al (2019) Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates. J Infect Dis 220(5):735\u2013742","journal-title":"J Infect Dis"},{"key":"1548_CR75","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.antiviral.2016.01.006","volume":"127","author":"HA Rothan","year":"2016","unstructured":"Rothan HA, Bahrani H, Abdulrahman AY et al (2016) Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo. Antiviral Res 127:50\u201356","journal-title":"Antiviral Res"},{"issue":"5","key":"1548_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126360","volume":"10","author":"HA Rothan","year":"2015","unstructured":"Rothan HA, Bahrani H, Mohamed Z et al (2015) A combination of doxycycline and ribavirin alleviated chikungunya infection. PLoS One 10(5):e0126360","journal-title":"PLoS One"},{"key":"1548_CR77","doi-asserted-by":"crossref","unstructured":"Roques P, Fritzer A, Dereuddre-Bosquet N et al (2022) Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera. JCI Insight 7(14).","DOI":"10.1172\/jci.insight.160173"},{"issue":"6","key":"1548_CR78","doi-asserted-by":"publisher","first-page":"e83527","DOI":"10.1172\/jci.insight.83527","volume":"2","author":"P Roques","year":"2017","unstructured":"Roques P, Ljungberg K, K\u00fcmmerer BM et al (2017) Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. JCI Insight 2(6):e83527","journal-title":"JCI Insight"},{"key":"1548_CR79","doi-asserted-by":"crossref","unstructured":"Roques P, Thiberville SD, Dupuis-Maguiraga L et al (2018) Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection. Viruses 10(5)","DOI":"10.3390\/v10050268"},{"issue":"39","key":"1548_CR80","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1016\/j.vaccine.2015.07.099","volume":"33","author":"PA Rudd","year":"2015","unstructured":"Rudd PA, Raphael AP, Yamada M et al (2015) Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm. Vaccine 33(39):5172\u20135180","journal-title":"Vaccine"},{"key":"1548_CR81","doi-asserted-by":"crossref","unstructured":"Safronetz D, Santiago RA, Bavaresco SPP et al (2025) Clinical manifestations associated with the chronic phase of Chikungunya Fever: A systematic review of prevalence. PLoS Negl Trop Dis 19(2)","DOI":"10.1371\/journal.pntd.0012810"},{"key":"1548_CR82","doi-asserted-by":"crossref","unstructured":"Sahoo B, Chowdary TK (2019) Conformational changes in Chikungunya virus E2 protein upon heparan sulfate receptor binding explain mechanism of E2-E1 dissociation during viral entry. Biosci Rep 39(6)","DOI":"10.1042\/BSR20191077"},{"issue":"2","key":"1548_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012810","volume":"19","author":"RA Santiago","year":"2025","unstructured":"Santiago RA, Bavaresco SPP, Citrangulo SG et al (2025) Clinical manifestations associated with the chronic phase of chikungunya fever: a systematic review of prevalence. PLoS Negl Trop Dis 19(2):e0012810","journal-title":"PLoS Negl Trop Dis"},{"key":"1548_CR84","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.2147\/DDDT.S366112","volume":"16","author":"C Schmidt","year":"2022","unstructured":"Schmidt C, Schnierle BS (2022) Chikungunya Vaccine Candidates: Current Landscape and Future Prospects. Drug Des Devel Ther 16:3663\u20133673","journal-title":"Drug Des Devel Ther"},{"issue":"2440110394","key":"1548_CR85","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","volume":"06","author":"M Schneider","year":"2023","unstructured":"Schneider M, Narciso-Abraham M, Hadl S et al (2023) Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 06(2440110394):2138\u20132147","journal-title":"Lancet"},{"key":"1548_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1413250","volume":"15","author":"MS Shaikh","year":"2024","unstructured":"Shaikh MS, Faiyazuddin M, Khan MS et al (2024) Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions. Front Microbiol 15:1413250","journal-title":"Front Microbiol"},{"issue":"2","key":"1548_CR87","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00253-018-9488-1","volume":"103","author":"V Sharma","year":"2019","unstructured":"Sharma V, Kaushik S, Pandit P et al (2019) Green synthesis of silver nanoparticles from medicinal plants and evaluation of their antiviral potential against chikungunya virus. Appl Microbiol Biotechnol 103(2):881\u2013891","journal-title":"Appl Microbiol Biotechnol"},{"issue":"26","key":"1548_CR88","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1016\/j.vaccine.2023.04.064","volume":"41","author":"CA Shaw","year":"2023","unstructured":"Shaw CA, August A, Bart S et al (2023) A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. Vaccine 41(26):3898\u20133906","journal-title":"Vaccine"},{"issue":"1","key":"1548_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34514-4","volume":"8","author":"E Silva-Filho","year":"2018","unstructured":"Silva-Filho E, Okano AH, Morya E et al (2018) Neuromodulation treats chikungunya arthralgia: a randomized controlled trial. Sci Rep 8(1):16010","journal-title":"Sci Rep"},{"issue":"3","key":"1548_CR90","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1172\/JCI84417","volume":"127","author":"LA Silva","year":"2017","unstructured":"Silva LA, Dermody TS (2017) Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest 127(3):737\u2013749","journal-title":"J Clin Invest"},{"key":"1548_CR91","doi-asserted-by":"crossref","unstructured":"Singh J, Dinkar A, Kumar N et al (2024) Dengue Fever Related Reactive Thrombocytosis in Young Male: A Case Report and Review Literature. Cardiovasc Hematol Disord Drug Targets","DOI":"10.2174\/011871529X325967240916075554"},{"issue":"12","key":"1548_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012713","volume":"18","author":"AC Sloof","year":"2024","unstructured":"Sloof AC, Boer M, Vondeling GT et al (2024) Strategic vaccination responses to chikungunya outbreaks in Rome: insights from a dynamic transmission model. PLoS Negl Trop Dis 18(12):e0012713","journal-title":"PLoS Negl Trop Dis"},{"key":"1548_CR93","doi-asserted-by":"publisher","first-page":"105487","DOI":"10.1016\/j.antiviral.2022.105487","volume":"02","author":"Y Suzuki","year":"2023","unstructured":"Suzuki Y (2023) Interferon-induced restriction of Chikungunya virus infection. Antiviral Res 02:210:105487","journal-title":"Antiviral Res"},{"key":"1548_CR94","doi-asserted-by":"crossref","unstructured":"Tanaka A, Tumkosit U, Nakamura S et al (2017) Genome-Wide Screening Uncovers the Significance of N-Sulfation of Heparan Sulfate as a Host Cell Factor for Chikungunya Virus Infection. J Virol 91(13)","DOI":"10.1128\/JVI.00432-17"},{"key":"1548_CR95","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3389\/fimmu.2018.02622","volume":"9","author":"CD Thompson","year":"2018","unstructured":"Thompson CD, Matta B, Barnes BJ (2018) Therapeutic Targeting of IRFs: Pathway-Dependence or Structure-Based? Front Immunol 9:2622","journal-title":"Front Immunol"},{"key":"1548_CR96","unstructured":"Te HS, Randall G, Jensen DM (2007) Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol Hepatol (N Y). 3(3):218\u2013225"},{"key":"1548_CR97","doi-asserted-by":"crossref","unstructured":"The Lancet Infectious D (2025) More data needed on the FDA\u2019s decision to suspend Ixchiq. Lancet Infect Dis","DOI":"10.1016\/S1473-3099(25)00552-3"},{"issue":"12","key":"1548_CR98","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/infdis\/jiu114","volume":"209","author":"I Tretyakova","year":"2014","unstructured":"Tretyakova I, Hearn J, Wang E et al (2014) DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J Infect Dis 209(12):1882\u201390","journal-title":"J Infect Dis"},{"issue":"1","key":"1548_CR99","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00253-022-12280-8","volume":"107","author":"SK Tsai","year":"2023","unstructured":"Tsai SK, Hsu YL, Chiao DJ et al (2023) Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells. Appl Microbiol Biotechnol 107(1):219\u2013232","journal-title":"Appl Microbiol Biotechnol"},{"key":"#cr-split#-1548_CR100.1","unstructured":"Valneva Provides Update on Chikungunya Vaccine IXCHIQ\u00ae: Valneva (2026) [updated January 19, 2026"},{"key":"#cr-split#-1548_CR100.2","unstructured":"cited 2026 May 19]. Available from: https:\/\/valneva.com\/press-release\/valneva-provides-update-on-chikungunya-vaccine-ixchiq\/"},{"key":"1548_CR101","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijid.2017.03.006","volume":"58","author":"B Wahid","year":"2017","unstructured":"Wahid B, Ali A, Rafique S, Idrees M (2017) Global expansion of chikungunya virus: mapping the 64-year history. Int J Infect Dis 58:69\u201376","journal-title":"Int J Infect Dis"},{"issue":"10","key":"1548_CR102","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S1473-3099(20)30238-3","volume":"20","author":"N Wressnigg","year":"2020","unstructured":"Wressnigg N, Hochreiter R, Zoihsl O et al (2020) Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. Lancet Infect Dis 20(10):1193\u20131203","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"1548_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003764","volume":"9","author":"IK Yoon","year":"2015","unstructured":"Yoon IK, Alera MT, Lago CB et al (2015) High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl Trop Dis 9(5):e0003764","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"1548_CR104","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/art.40403","volume":"70","author":"A Zaid","year":"2018","unstructured":"Zaid A, G\u00e9rardin P, Taylor A et al (2018) Chikungunya Arthritis: Implications of Acute and Chronic Inflammation Mechanisms on Disease Management. Arthritis Rheumatol 70(4):484\u2013495","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1548_CR105","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.azn.2025.01.003","volume":"1","author":"D Zhang","year":"2025","unstructured":"Zhang D, Qiu Z, Hao Y et al (2025) Progress in the molecular epidemiology of chikungunya virus. Anim Zoonoses 1(2):164\u2013169","journal-title":"Anim Zoonoses"},{"issue":"1","key":"1548_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.imj.2025.100231","volume":"5","author":"X Zhang","year":"2026","unstructured":"Zhang X, Li X, Jiang T, Fu J (2026) A brief review of chikungunya fever: from molecular virology to countermeasures. Infect Med 5(1):100231","journal-title":"Infect Med"},{"key":"1548_CR107","doi-asserted-by":"publisher","first-page":"567134","DOI":"10.2147\/IDR.S567134","volume":"19","author":"C Zhao","year":"2026","unstructured":"Zhao C, Ge Z, Zhang T et al (2026) Chikungunya Virus in 2025: Epidemiology, Immunopathogenesis, and Vaccine Development - A Narrative Review. Infect Drug Resist 19:567134","journal-title":"Infect Drug Resist"}],"container-title":["Folia Microbiologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12223-026-01548-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12223-026-01548-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12223-026-01548-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:01:45Z","timestamp":1783659705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12223-026-01548-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":110,"alternative-id":["1548"],"URL":"https:\/\/doi.org\/10.1007\/s12223-026-01548-5","relation":{},"ISSN":["0015-5632","1874-9356"],"issn-type":[{"value":"0015-5632","type":"print"},{"value":"1874-9356","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}